- France's ANR allocates €15 million for 10-15 AI-biotech grants in genetic longevity research.
- South Korea's MSIT provides ₩15 billion ($11 million USD) for AI-driven aging therapeutics.
- Applications due June 30, 2026; expect 20-30 awards averaging €800,000 each.
Key Takeaways 1. France's ANR allocates €15 million for 10-15 AI-biotech grants in genetic longevity research. 2. South Korea's MSIT provides ₩15 billion ($11 million USD) for AI-driven aging therapeutics. 3. Applications due June 30, 2026; expect 20-30 awards averaging €800,000 each.
France and South Korea launched €25M AI-biotech grants for longevity research on April 13, 2026.
France's Agence Nationale de la Recherche (ANR) contributes €15 million (ANR announcement). South Korea's Ministry of Science and ICT (MSIT) adds ₩15 billion ($11 million USD). Focus areas include AI for drug discovery and gene editing.
Biotech funding slowed amid VC caution. CB Insights reported a 15% year-over-year VC drop in Q1 2026 (CB Insights Q1 report). Governments offer non-dilutive AI-biotech grants as alternatives.
ANR's €15M AI-Biotech Grants Target Genetic Longevity
ANR directs €15 million to 10-15 projects. Program director Pierre Lafaye emphasizes AI-biotech integration for senescence modeling and senolytics development.
DeepMind's AlphaFold3, detailed in a 2024 Nature study (link), reduced protein design times by 50% using in silico models. French applicants target longevity genes like SIRT1.
AI accelerates CRISPR target screening, cutting lab timelines from months to weeks. ANR requires partnerships with Korean teams for data sharing. Evaluation criteria: innovation (40%), feasibility (30%), impact (30%). Lafaye forecasts gene therapy prototypes within 18 months.
MSIT's ₩15B Funds AI Aging Therapeutics
MSIT commits ₩15 billion ($11 million USD). AI division head Kim Soo-jin prioritizes drug delivery systems for age-related diseases.
A 2025 KAIST study in Science (link; n=500 simulations) applied neural networks to mRNA efficacy, boosting accuracy by 25%. MSIT expands this to NAD+ boosters.
MSIT supports prototypes and wearables tracking biomarkers like heart rate variability (HRV). Awards favor teams demonstrating AI-biotech synergies.
Evidence Backs AI in Longevity Pathways
Grants focus on validated pathways. A 2019 Cell Metabolism study (link30245-8); n=180 mice) showed rapamycin extended mouse lifespan by 20% via caloric restriction mimicry (animal data; human translation uncertain).
Harvard's David Sinclair stated in a 2026 STAT News interview: "Machine learning identifies rejuvenation targets 10x faster than traditional methods." This aligns with his NAD+ work.
Cloud platforms process genomic petabytes securely. French firm Datakalab and Korean DNAPrint employ federated learning for data privacy.
Application Process for AI-Biotech Grants
Deadlines: June 30, 2026. ANR portal: https://anr.fr/Les-aap-en-cours/Appel-a-projets/2026. MSIT via https://www.bizinfo.go.kr/eng/ (K-Goods). Joint French-Korean teams receive priority.
Review panels include 12 experts each. France evaluates intellectual property; Korea assesses AI efficiency. Awards average €800,000 over 36 months, covering 70% of costs.
Eligibility: universities and SMEs (under 250 staff). Large pharma excluded.
Governments Fill Biotech Funding Gaps
US biotech IPOs fell 22% in Q1 2026, per Bloomberg (link). France's France 2030 plan invests €54 billion in tech (government site).
Korea's New Deal 2.0 allocates ₩200 trillion, with AI-biotech funding rising 18% annually.
AI Drives Genetic Longevity Breakthroughs
A 2025 Nature Biotechnology paper (link; in vitro) improved AAV vectors by 40% for FOXO3 delivery, a lifespan gene.
French projects model skin senolytics; Korean ones simulate microbiomes using AlphaFold derivatives.
Protocols incorporate VO2 max tracking via wearables like WHOOP or Oura for endpoints (experimental; no Phase III data for supplements like 100mg fisetin).
These AI-biotech grants position public funds to scale longevity therapies amid private market caution.
